Mobile Lads Corp. (MOBO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 1.31 Million USD | -70.23% |
| 2021 | 4.41 Million USD | -17.07% |
| 2020 | 5.31 Million USD | 24.05% |
| 2019 | 4.28 Million USD | 0.0% |
| 2016 | 367.83 Thousand USD | 29.19% |
| 2015 | 284.71 Thousand USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 10.8 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 1.56 Million USD | 7.79% |
| 2023 Q2 | 1.67 Million USD | 7.06% |
| 2022 Q3 | 1.31 Million USD | 14.4% |
| 2022 FY | 1.31 Million USD | -70.23% |
| 2022 Q1 | 1.14 Million USD | 0.0% |
| 2022 Q4 | 1.44 Million USD | 10.19% |
| 2022 Q2 | 1.14 Million USD | 0.59% |
| 2021 FY | 4.41 Million USD | -17.07% |
| 2020 FY | 5.31 Million USD | 24.05% |
| 2019 FY | 4.28 Million USD | 0.0% |
| 2017 Q1 | 491.8 Thousand USD | 33.7% |
| 2016 Q3 | 618.07 Thousand USD | 27.13% |
| 2016 Q1 | 317.35 Thousand USD | 11.47% |
| 2016 FY | 367.83 Thousand USD | 29.19% |
| 2016 Q2 | 486.16 Thousand USD | 53.19% |
| 2016 Q4 | 367.83 Thousand USD | -40.49% |
| 2015 FY | 284.71 Thousand USD | 0.0% |
| 2015 Q1 | 14.3 Thousand USD | 0.0% |
| 2015 Q2 | 202.95 Thousand USD | 1319.27% |
| 2015 Q4 | 284.71 Thousand USD | 12.73% |
| 2015 Q3 | 252.56 Thousand USD | 24.44% |
| 2014 Q4 | - USD | -100.0% |
| 2014 Q3 | 7700.00 USD | 2.67% |
| 2014 Q2 | 7500.00 USD | 0.0% |
| 2014 FY | - USD | -100.0% |
| 2014 Q1 | 7500.00 USD | 0.0% |
| 2013 FY | 10.8 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -4688.018% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 86.124% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 98.188% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -62.402% |
| Rebus Holdings, Inc. | 5.24 Million USD | 74.943% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.774% |
| Qrons Inc. | 1.48 Million USD | 11.77% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -7.118% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 98.247% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2838.735% |
| Skye Bioscience, Inc. | 14.07 Million USD | 90.666% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.536% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 86.292% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -211.574% |
| SQZ Biotechnologies Company | 50.03 Million USD | 97.375% |
| Intellipharmaceutics International Inc. | 12 Million USD | 89.062% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 65.896% |
| Mesoblast Limited | 188.44 Million USD | 99.303% |
| Marizyme, Inc. | 26.67 Million USD | 95.076% |
| Genus plc | 485 Million USD | 99.729% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 77.519% |
| Pharming Group N.V. | 244.07 Million USD | 99.462% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 34.656% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 47.801% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 65.434% |
| ContraFect Corporation | 32.53 Million USD | 95.962% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 33.706% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 65.684% |
| IMV Inc. | 37.93 Million USD | 96.537% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 88.848% |
| MultiCell Technologies, Inc. | 1617.67 USD | -81096.845% |
| ONE Bio Corp. | 27.49 Million USD | 95.223% |
| Accustem Sciences Inc. | 1.07 Million USD | -21.706% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 98.303% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 37.898% |
| Q BioMed Inc. | 8.13 Million USD | 83.85% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.416% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 74.476% |
| Biomind Labs Inc. | 1.49 Million USD | 12.352% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.894% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 85.474% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 92.863% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 8.394% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -824.379% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -553.104% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 77.14% |
| GB Sciences, Inc. | 5.41 Million USD | 75.755% |
| Alpha Cognition Inc. | 7.16 Million USD | 81.667% |
| HST Global, Inc. | 593.59 Thousand USD | -121.279% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -4.313% |
| Halberd Corporation | 728.71 Thousand USD | -80.247% |
| Enzolytics Inc. | 365.26 Million USD | 99.64% |
| Agentix Corp. | 2.51 Million USD | 47.681% |
| Resverlogix Corp. | 67.39 Million USD | 98.051% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -56.605% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.705% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 23.367% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 94.692% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 88.965% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 64.163% |
| AVAX Technologies, Inc. | 3.99 Million USD | 67.111% |
| Zenith Capital Corp. | 27.56 Thousand USD | -4664.398% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.901% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -450.377% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 64.826% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -92.925% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 51.561% |
| Kadimastem Ltd | 3.5 Million USD | 62.524% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1862.523% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 97.387% |
| BioStem Technologies, Inc. | 15.9 Million USD | 91.741% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -182.655% |
| LadRx Corporation | 2.2 Million USD | 40.31% |
| Cell Source, Inc. | 15.8 Million USD | 91.69% |
| Regen BioPharma, Inc. | 5.45 Million USD | 75.933% |
| Regen BioPharma, Inc. | 5.45 Million USD | 75.933% |
| NovAccess Global Inc. | 7.86 Million USD | 83.29% |
| Affymax, Inc. | 8.87 Million USD | 85.193% |
| Itoco Inc. | 1.65 Million USD | 20.546% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 35.976% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 78.286% |
| CytoDyn Inc. | 127.89 Million USD | 98.973% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3042.412% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 16.144% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 88.108% |
| SYBLEU INC | 681.41 Thousand USD | -92.761% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 78.474% |
| International Stem Cell Corporation | 5.27 Million USD | 75.109% |
| Bioxytran, Inc. | 3.24 Million USD | 59.578% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -109.888% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 71.552% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.796% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 94.101% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 35.148% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 76.022% |
| Neutra Corp. | 973.52 Thousand USD | -34.921% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 95.473% |
| PureTech Health plc | 125.58 Million USD | 98.954% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 65.04% |
| IXICO plc | 1.9 Million USD | 30.879% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 93.602% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.729% |
| CSL Limited | 18.62 Billion USD | 99.993% |
| Cellectis S.A. | 249.36 Million USD | 99.473% |